WO2007029345A1 - Inhibiteur de l'activité de la tyrosinase - Google Patents

Inhibiteur de l'activité de la tyrosinase Download PDF

Info

Publication number
WO2007029345A1
WO2007029345A1 PCT/JP2005/017373 JP2005017373W WO2007029345A1 WO 2007029345 A1 WO2007029345 A1 WO 2007029345A1 JP 2005017373 W JP2005017373 W JP 2005017373W WO 2007029345 A1 WO2007029345 A1 WO 2007029345A1
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosinase activity
activity inhibitor
acid
vitamin
weight
Prior art date
Application number
PCT/JP2005/017373
Other languages
English (en)
Japanese (ja)
Inventor
Shigeki Sawamura
Original Assignee
Kobayashi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co., Ltd. filed Critical Kobayashi Pharmaceutical Co., Ltd.
Publication of WO2007029345A1 publication Critical patent/WO2007029345A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to a tyrosinase activity inhibitor containing piotins as an active ingredient.
  • tyrosinase is widely distributed in nature such as microorganisms, plants and animals, and melanin causing freckles and freckles is synthesized by its enzymatic action. For this reason, the prevention and treatment of stains and freckles have been carried out by inhibiting tyrosinase activity and production.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2004-217655
  • An object of the present invention is to provide an excellent tyrosinase activity inhibitor.
  • the present invention relates to the following tyrosinase activity inhibitors.
  • Item 1 A tyrosinase activity inhibitor containing piotin as an active ingredient.
  • Item 2 The tyrosinase activity inhibitor according to Item 1, further comprising ascorbic acids.
  • Item 3 The tyrosinase activity inhibitor according to Item 2, comprising 40 to 300,000 parts by weight of ascorbic acid with respect to 1 part by weight of piotin.
  • Item 4 The tyrosinase activity inhibitor according to any one of Items 1 to 3, further comprising vitamin E.
  • Item 5 The tyrosinase activity inhibitor according to Item 4, comprising 2 to 30,000 parts by weight of vitamin E with respect to 1 part by weight of piotins.
  • a tyrosin according to any one of Items 1 to 5, which is a solid preparation containing one or more selected from the group power of sweetener and water-swelling substance power Ze activity inhibitor.
  • the sweetener is selected from the group consisting of sucrose, fructose, oligosaccharide, saccharin, sodium saccharin, aspartame, xylitol, mannitol, erythritol, sucralose, maltitol, sorbitol, trehalose, and stevia.
  • Item 7 The tyrosinase activity inhibitor according to Item 6, wherein the tyrosinase activity inhibitor is a species or more.
  • the water-swellable substance is hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropenoremethinorescenellose, crystalline senorelose, canolemellose, salt of force nomellose, croscarmellose sodium, copolyvidone, polybylpyrrolidone, Item 8.
  • peiotine is an active ingredient and essential.
  • Piotins include piotin, piotin salts, piotin derivatives and the like, and preferred are piotin and piotin salts.
  • Piotin is a known compound, and both synthetic products and natural products can be used in the present invention.
  • As the salt of piotine any salt suitable for oral administration can be used in the present invention. Examples of the salt of piotine are alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; ammonium salt.
  • a derivative of piotin a derivative suitable for oral intake can be used.
  • piotin is 6-piotinamide hexanoe 6- [6-Piotinamide hexamide] hexanoate, and 2-Piotinamide ethaneol and other amide linkages of piotin.
  • Piotin is preferably used in the present invention. Further, in the present invention, one kind selected for the ability of piotin can be used alone or in combination of two or more kinds.
  • tyrosinase activity inhibitor of the present invention tyrosinase activity is enhanced when ascorbic acid and / or vitamin E is used in combination with the active ingredient piotins.
  • Ascorbic acids include ascorbic acid, ascorbic acid salts, ascorbic acid derivatives, and the like, preferably ascorbic acid and ascorbic acid salts.
  • Ascorbic acid is a known compound, and both synthetic and natural products can be used in the present invention. Any ascorbic acid salts and derivatives may be used in the present invention as long as they are suitable for oral administration.
  • the ascorbic acid, ascorbate and ascorbic acid derivative are all preferably L-form.
  • Examples of ascorbic acid salts include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; ammonium salt; hydrochloride salt, nitrate salt, sulfate salt, etc.
  • Mineral acid salts preferably sodium ascorbate and calcium ascorbate.
  • derivatives of ascorbic acid include ascorbic acid monostearate, ascorbic acid monopalmitate, ascorbic acid monoalkyl such as ascorbic acid monooleate; ascorbic acid monoalkenyl ester; ascorbic acid distearate, ascorbic acid dipalmitate, ascorbic acid dioleate Ascorbic acid dialkyl ester; ascorbic acid tristearate, ascorbic acid tripalmitate, ascorbic acid trioleate and other ascorbic acid trialkyl ester; ascorbic acid trialkenyl ester; ascorbyl sulfate; Ascorbyl sulfate ester such as potassium corsolsulfate, magnesium corsolsulfate, calcium iscorbyl sulfate; Ascorbyl phosphates such as ascorbyl phosphate; sodium ascorbyl phosphate, potassium ascorbyl phosphate, magnesium ascorbyl phosphate
  • Vitamin E includes vitamin E, vitamin E salts, vitamin E derivatives and the like, preferably vitamin E and vitamin E salts.
  • Vitamin E can be used in the present invention for both synthetic and natural products. Any salt and derivative of vitamin E can be used in the present invention as long as they are suitable for oral administration.
  • Vitamin E has tocopherols and tocotrienols as homologues depending on the number and position of methyl groups bound to the chroman nucleus and the type of side chain, and a ;, ⁇ , ⁇ , and ⁇ , respectively. There are d-forms and dl-forms as optical isomers, both of which can be used as vitamin Es.
  • salts and derivatives of vitamin E include the above-mentioned isomers.
  • the preferred ⁇ structural isomer is ⁇ .
  • vitamin ⁇ salts include vitamin ⁇ metal salts.
  • derivatives of vitamin ⁇ are tocopherol acetate, tocopherol succinate, tocopherol succinate, tocopherol nicotinate and the like.
  • one kind selected from the strength of vitamin E can be used alone or in combination of two or more kinds.
  • a pharmaceutically acceptable carrier can be added to the piotins that are active ingredients as necessary.
  • Tyrosinase activity inhibition ⁇ force amount of Piochin compound is a particularly restricted as long as the tyrosinase activity inhibition effect is exhibited in the dosage usually 0.000005 to 100 weight 0/0, preferably ⁇ I or 0.0005 to 90 weight 0 / 0 , more preferably 0.005 to 80% by weight. When the amount of piotin is within these ranges, a remarkable tyrosinase activity inhibitory effect is obtained.
  • oral compositions containing the tyrosinase activity inhibitor of the present invention for example, foods (including functional foods, health foods, hospital foods, etc.) can be used to prevent spots or freckles It is considered effective for treatment.
  • Tyrosinase activity inhibitor of the present invention preferred ⁇ Asukorubin distribution total amount of acids from 0.1 to 99.9995 wt 0/0, more preferably 1 to 80 weight 0/0
  • the amount of the preferred vitamin E group is 0.005 to 99.9995 wt 0/0, more preferably 1 to 80 weight 0/0.
  • tyrosinase activity inhibitor of the present invention it is preferable to combine 40 to 300,000 parts by weight of asconolevic acid with 1 part by weight of piotins, preferably 100 to 50,000 parts by weight. L is more preferable than 140 to 4000 parts by weight.
  • the blending amount of piotin and ascorbic acid is within these ranges, a stronger tyrosinase activity inhibitory effect and a stain and freckles inhibitory effect can be obtained.
  • tyrosinase activity inhibitor of the present invention it is preferable to blend 2 to 30000 parts by weight of vitamin E with 1 part by weight of piotins. More preferable It is more preferable to add 2 to 600 parts by weight. When the amount of vitamins and vitamin E are within these ranges, stronger tyrosinase activity inhibitory effect and stain / freckle control effect can be obtained.
  • the tyrosinase activity inhibitor of the present invention may contain other components in addition to the above-mentioned piotins.
  • Vitamin B includes thiamine hydrochloride, thiamine nitrate, fursultiamine hydrochloride, bisthiamine nitrate, thiamine disulfide, dicetiamine hydrochloride, octothiamine, bisbutiamine, bisbenchamine, fursultiamine, benfotiamine, riboflavin, riboflavin phosphate Sodium, riboflavin butyrate, pyridoxine hydrochloride, pyridoxal phosphate, cyanobalamine, hydroxocobalamin acetate, mecobalamin and the like can be used alone or in combination of two or more.
  • the amount of vitamin B is appropriately determined based on the amount that the daily dose is 0.001 to 300 mg, preferably 0.06 to 200 mg, more preferably 1.5 to 150 mg. Can be set.
  • sweeteners include sucrose, fructose, oligosaccharide, saccharin, saccharin sodium, aspartame, and xylose.
  • Ritonole mannito nore, erythrito nore, sucralose, manole titonore, sonorebitonore, toreno, loin, stevia, amachiya, amachiya powder, liquid sugar, reduced maltose starch syrup, fructose glucose liquid sugar, glycine, brown sugar, high fructose liquid sugar, Examples include honey, simple syrup, glucose fructose liquid sugar, powdered reduced maltose starch syrup, starch syrup, thaumatin, dipotassium glycyrrhizinate, and acesulfame K. These can be used alone or in combination of two or more.
  • the amount of sweetening agent, Te tyrosinase activity inhibitor ⁇ antifreeze ⁇ of the present invention from 0.1 to 99.9995 wt 0/0, preferably ⁇ or 1 to 90 weight 0/0.
  • Water swellable substances include hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropinoremethinorescenellose, crystalline senorelose, canolemellose, canolemellose salt, croscarmellose sodium, copolyvidone, polybulol pyrrolidone, cros polybulur pyrrolidone, A methyl cellulose etc. can be illustrated and it can be used individually by 1 type or in combination of 2 or more types.
  • the amount of water-swellable material, in tyrosinase activity inhibitor of the present invention 0.005 to 50 weight 0/0, preferably from 0.05 to 20 weight 0/0.
  • pantothenic acid pantothenate (calcium pantothenate, calcium pantothenate type S, sodium pantothenate, etc.), nicotinamide, nicotinic acid, nontethein, pantethine, phosphopantete Tin, hydroquinones (nodroquinone, arbutin, etc.), darcosamines (darcosamine, acetylyldarcosamine, glucosamine alkyl ether, etc.), ubiquinones (coenzyme Q, coenzyme Q,
  • Dartathiones plant extracts, folic acid, orotic acid, gamma oryzanol, ursodeoxycholic acid, glucuronolatatone, glucuronic acid amide, potassium aspartate, magnesium aspartate, aspirin, Cetaminophen, ethenzamide, ibuprofen, ketoprofen, indomethacin, cimetidine, famotidine, isopropylantipyrine, diphenhydramine hydrochloride, d-chlorfelamine maleate, dl-chlorfelamin maleate, mequitazine, clemastine fumarate, clovelastine hydrochloride, Phenylpropanolamine hydrochloride, dextromethorphan hydrobromide, codine phosphate, dihydrocodine phosphate, noss force pin, nos force pin, dl—methinoreph , Guaifenesin, lysozy
  • the tyrosinase activity inhibitor of the present invention can be prepared in various dosage forms according to conventional methods.
  • oral preparations such as tablets, coated tablets, powders, granules, fine granules, capsules, pills, liquids, suspensions, emulsions, jellies, chewables, and soft tablets.
  • granules, powders, fine granules, tablets, coated tablets, jellies, chewables, soft tablets is there.
  • the preparation can be produced by a preparation method generally known in this field, using an appropriate preparation carrier as necessary.
  • the carrier used here include various ones commonly used in ordinary drugs, such as excipients, binders, disintegrants, lubricants, solvents, sweeteners, and the like.
  • additives such as a colorant, a flavoring agent, a flavoring agent, a surfactant, a moisturizing agent, a preservative, a pH adjuster, and a thickening agent can be added to the preparation.
  • examples of carriers include lactose, sucrose, sodium chloride sodium salt, glucose, urea, starch, calcium carbonate, strength oline, crystals.
  • Cellulose carboxylic acid, methylcellulose, glycerin, sodium alginate, arabic gum, talc, calcium monohydrogen phosphate, calcium hydrogen phosphate, sodium hydrogen phosphate, dipotassium phosphate, potassium dihydrogen phosphate, dihydrogen phosphate Excipients such as calcium, sodium dihydrogen phosphate, calcium sulfate, calcium lactate, cacao butter, simple syrup, sugar solution, starch solution, gelatin solution, polybulal alcohol, polybull ether, polybulurpyrrolidone, cross-poly Bull pyrrolidone, hydroxypropyl cellulose, low substituted hydroxy Pinolecenolose, hydroxypropinoremethylolosenolellose, hydroxycellulose cellulose, carboxyvinyl polymer, crystalline cellulose, powdered cellulose, crystalline cellulose, canolemellose sodium, canoleboxymethylenoresenorose, shellac, methinoresenorose Binders such as ethyl cellulose
  • Capsules are prepared by mixing the active ingredient with the various carriers exemplified above and filling hard gelatin capsules, soft capsules, and the like.
  • the liquid preparation may be an aqueous or oily suspension, solution, syrup or elixir.
  • the liquid preparation is prepared according to a conventional method using usual additives.
  • Examples of the flavoring agent or perfume include, for example, heart power oil, eucalyptus oil, keihi oil, wikiyo oil, timber oil, orange oil, lemon oil, rose oil, fruit flavor, mint flavor, peppermint powder, dl-menthol 1 menthol.
  • Examples include sour agents (taenoic acid, malic acid, tartaric acid) and mixtures thereof.
  • the tyrosinase activity inhibitor of the present invention is administered orally.
  • the dose of each active ingredient in the present invention can be appropriately selected according to the usage, the age of the user, sex, the degree of stains and freckles, and other conditions.
  • about 0.55 (0.01 for adults) to 5 mg, preferably about 0.0025 (0.05 for adults) to 5 mg, more preferably 0.005 per day of piotins. (0.5 for adults) can be administered at a dose of about 5 mg to 5 mg.
  • the ascorbic acids are about 10 (200 for adults) to about 3000 mg, preferably about 25 (500 for adults) to about 2500 mg, more preferably about 35 (adults). In the case of 700) to 2000 mg.
  • vitamin E When vitamin E is added, vitamin E is added in an amount of about 0.5 (10 for adults) to about 300 mg, preferably about 1 (20 for adults) to about 250 mg, more preferably The dose is 1.5 (30 for adults) to 200 mg.
  • the tyrosinase activity inhibitor of the present invention should be administered 1 to 3 times a day. Can do.
  • the tyrosinase activity inhibitor of the present invention may be a single preparation containing all components, and each component is appropriately divided into a plurality of preparations such as a two-part preparation and a three-part preparation. You can also In addition, each component can be appropriately divided into a plurality of preparations, which can be contained in a container suitable for use and can be administered simultaneously or sequentially.
  • a tyrosinase activity inhibitor that is highly safe for living organisms and can be used to suppress freckles can be provided. Suppression of spots and freckles includes suppression of the generation of spots and freckles, and the color of spots and freckles becoming lighter.
  • FIG. 1 is a graph showing the inhibition rate in the tyrosinase activity inhibition test of Test Example 1 and a table showing the sample solution composition.
  • shaft of a graph is an inhibition rate and the unit of the numerical value of a table
  • surface is mg.
  • Test Example 1 Tyrosinase activity inhibition test
  • PBS buffer (hereinafter sometimes referred to as PBS)
  • B16 melanoma cells were seeded in a 96-well microphone-mouthed plate at a dose of 5 ⁇ 10 4 cells Zwell (200 ⁇ l Zwell) and cultured overnight to establish the cells.
  • the medium in the well was removed, 50 A of reagent A was added, and the cells were dissolved.
  • sample solution was added in a volume of 50 ⁇ 1Z.
  • Reagent A 50 ⁇ 1well and sample solution 50 ⁇ 1well were added to an empty 96-well microphone opening plate.
  • B16 melanoma cells were seeded in a 96-well microphone-mouthed plate at a dose of 5 ⁇ 10 4 cells Zwell (200 ⁇ l Zwell) and cultured overnight to establish the cells.
  • the medium in the well was removed, 50 A of reagent A was added, and the cells were dissolved.
  • sample solution was added in a volume of 50 ⁇ 1Z.
  • Reagent B 50 ⁇ l was added to each sample plate well and each blank plate 1 well. Grow specimen plate, blank plate 1 and blank plate 2 at 37 ° C for 12 hours.
  • Blank plate 2 was centrifuged at 2000 rpm for 3 minutes, and the supernatant was removed!
  • the blank plate 2 was mixed with 150 ⁇ l / well PBS and mixed.
  • A (well absorbance of plate with test sample) (well absorbance of blank plate 1 with test sample)
  • piotin is a substance having an action that inhibits tyrosinase activity (ascorbic acid, succinic acid d-a-tocopherol, L-cystine) and has a suitable action on skin metabolism (riboflavin butyrate, hydrochloric acid It was shown that the tyrosinase activity inhibitory action is stronger than that of the conventional product model combined with pyridoxine).
  • Example 5 the composition containing ascorbic acid, succinic acid d-a tocopherol and L-cysteine (conventional product model) contains ascorbic acid and cono, and succinic acid d- a tocopherol and piotin. It was shown that the prepared composition has a significantly stronger inhibitory effect on tyrosinase activity.
  • Test Example 2 Human Stain ⁇ Evaluation for freckle
  • Samples were prepared with the compositions shown in Table 1. That is, weighed each component shown in Table 1, After stirring and mixing, water was added and kneaded, and the mixture was granulated with a granulator and dried with a dryer to obtain a sample (granule).
  • Granules were produced in the same manner as in Test Example 2 with the components shown in Tables 3-6.
  • the present invention is useful in the field of tyrosinase activity inhibitors, or in the field of whitening that suppresses freckles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a pour objet un excellent inhibiteur de l'activité de la tyrosinase. L'invention concerne un inhibiteur de l'activité de la tyrosinase qui contient de la biotine ou son dérivé comme ingrédient actif ; l'inhibiteur de l'activité de la tyrosinase décrit ci-dessus qui contient en plus de l'acide ascorbique ou son dérivé ; l'inhibiteur de l'activité de la tyrosinase décrit ci-dessus qui contient en plus des vitamines E ; et l'inhibiteur de l'activité de la tyrosinase décrit ci-dessus caractérisé en ce qu'il est sous forme d'une préparation solide à usage interne, laquelle contient un ou plusieurs composants sélectionnés dans le groupe constitué d'édulcorants et de substances gonflant dans l'eau. L''inhibiteur de l'activité de la tyrosinase décrit ci-dessus est utile comme composition blanchissante.
PCT/JP2005/017373 2005-09-01 2005-09-21 Inhibiteur de l'activité de la tyrosinase WO2007029345A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005254161A JP2007063224A (ja) 2005-09-01 2005-09-01 チロシナーゼ活性阻害剤
JP2005-254161 2005-09-01

Publications (1)

Publication Number Publication Date
WO2007029345A1 true WO2007029345A1 (fr) 2007-03-15

Family

ID=37835482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/017373 WO2007029345A1 (fr) 2005-09-01 2005-09-21 Inhibiteur de l'activité de la tyrosinase

Country Status (2)

Country Link
JP (1) JP2007063224A (fr)
WO (1) WO2007029345A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004091473A (ja) * 2002-07-12 2004-03-25 Tadayasu Takada 色素沈着改善治療薬
US20050048012A1 (en) * 2003-08-26 2005-03-03 Roland Jermann Use of biotin or a biotin derivative for skin lightening purposes and for the treatment of senile lentigines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004091473A (ja) * 2002-07-12 2004-03-25 Tadayasu Takada 色素沈着改善治療薬
US20050048012A1 (en) * 2003-08-26 2005-03-03 Roland Jermann Use of biotin or a biotin derivative for skin lightening purposes and for the treatment of senile lentigines

Also Published As

Publication number Publication date
JP2007063224A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
US7410659B2 (en) Methods for the treatment of peripheral neural and vascular ailments
JP6265624B2 (ja) ルリコナゾール含有外用医薬組成物
KR102566670B1 (ko) 피부 색소 침착 억제제
ES2260293T3 (es) Composicion que comprende acido hidroxicitrico y garcinol para reduccion de peso.
JP5921664B2 (ja) 皮膚の乾燥予防または改善用経口剤
JP2005518381A (ja) 抹消神経・血管疾患の治療方法
CN101360487A (zh) 液体剂型中含硫药物的药物制剂
KR20070111478A (ko) 영양 보충을 위한 조성물과 방법
JP6716755B2 (ja) 外用組成物
ES2412274T3 (es) Composición que contiene un derivado de vitamina B6 estable
EP1514540B1 (fr) Agents de renforcement de tissus contenant du calcium et utilisation correspondante
JP4390428B2 (ja) 含カルシウム組織強化剤
JP2008088113A (ja) 美白組成物
JP2010132575A (ja) 美白剤およびその利用
WO2007026897A1 (fr) Composition orale et aliment pour la prévention ou le traitement de tâches cutanées ou tâches de rousseur
WO2007029345A1 (fr) Inhibiteur de l'activité de la tyrosinase
JP2008031094A (ja) Ｓｃｆ結合阻害剤
JP2010260808A (ja) 肌状態改善用経口医薬組成物
JP4988166B2 (ja) キサンチンオキシダーゼ阻害剤
JP2005298493A (ja) 肌あれ予防および／または治療用医薬組成物
AU2002352501B2 (en) Methods for the treatment of peripheral neural and vascular ailments
JP5339708B2 (ja) システイン類を有効成分とするマトリックスメタロプロテアーゼ−８阻害剤及び糖尿病患者又は耐糖能障害を有する者用の歯周病予防又は治療組成物
JP4771453B2 (ja) エッセンス剤形の皮膚外用剤
JP2004075558A (ja) 美白改善用キット
JP2006241030A (ja) エッセンス剤形の皮膚外用剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05785558

Country of ref document: EP

Kind code of ref document: A1